BioCentury | Jun 10, 2020
Emerging Company Profile

Autobahn: fine-tuning thyroid agonism to remyelinate axons

Autobahn, which launched with a $76 million series B Tuesday, joins at least six other companies with disclosed remyelination programs for multiple sclerosis. But the biotech thinks its prodrug, slated to enter the clinic next...
BioCentury | Apr 3, 2020
Distillery Therapeutics

IRE1 activation to treat cystic fibrosis and Pendred syndrome

DISEASE CATEGORY: Pulmonary; otologic INDICATION: Cystic fibrosis (CF); hearing loss Activating IRE1 could treat diseases caused by defective trafficking of membrane proteins to the cell surface, including CF and Pendred syndrome. Pendred syndrome is an...
BioCentury | Dec 19, 2019

SLC5A12 inhibition for rheumatoid arthritis

DISEASE CATEGORY: Autoimmune disease INDICATION: Rheumatoid arthritis (RA) Inhibiting the lactate transporter SLC5A12 could treat RA. In 87 patients with early RA, high levels of SLC5A12 RNA expression in the synovium was associated with increased...
BioCentury | Dec 6, 2019
Targets & Mechanisms

Emerging immuno-oncology mechanisms at ASH 2019

Researchers are finding new ways to monitor the immune system in hematologic diseases that could have implications for optimizing immuno-oncology therapies, according to BioCentury’s analysis of emerging targets at ASH 2019. In abstracts released ahead...
BioCentury | Sep 19, 2019
Distillery Therapeutics

Increasing SLC8B1 expression for Alzheimer's

DISEASE CATEGORY: Neurology INDICATION: Alzheimer's disease (AD) Promoting the expression of SLC8B1, a mediator of mitochondrial calcium efflux, could treat AD. Postmortem frontal cortex samples from patients with non-familial, sporadic AD had lower levels of...
BioCentury | Sep 18, 2019
Distillery Therapeutics

SLC7A11 and mGluR5 identified as targets for hepatic alcoholic steatosis

DISEASE CATEGORY: Hepatic INDICATION: Liver disease Inhibiting SLC7A11, which excretes glutamate from cells, or the glutamate receptor mGluR5 could treat alcoholic steatosis of the liver. Patients with alcoholic fatty liver disease had elevated plasma levels...
BioCentury | Aug 28, 2019
Translation in Brief

Guiding antibody-drug conjugates from circulation to cytoplasm

A linchpin for the efficacy of antibody-drug conjugates is ensuring the payload travels from the circulation, to the endosomal pathway, and ultimately into the cytoplasm. A new study by Stanford University researchers uncovers biological pathways...
BioCentury | Jun 1, 2019
Product Development

ASCO 2019 abstracts show solid tumor race heating up among bispecifics and CAR Ts

While strong progress in CAR T therapies will again feature at this year’s ASCO meeting, bispecific antibodies are having a moment -- making more inroads into solid tumors than CAR Ts and branching out via...
BioCentury | May 15, 2019
Distillery Therapeutics

Cystine degradation boosts immunotherapies in melanoma

DISEASE CATEGORY: Cancer INDICATION: Melanoma Patient sample and mouse studies suggest promoting ferroptosis by degrading cystine could enhance the efficacy of anti-PD-1 immunotherapies in melanoma. In melanoma patients, high tumor levels of SLC7A11 and SLC3A2,...
BioCentury | May 8, 2019
Translation in Brief

New Therapeutic Targets and Biomarkers: April 2019

New Therapeutic Targets and Biomarkers: April 2019 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database during April. Therapeutic targets are defined as any protein, gene or other molecule...
Items per page:
1 - 10 of 77